INHIBIKASE THERAPEUTICS INC. - COMMON STOCK

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

14 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

27 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Inhibikase Announces Expansion of Senior Leadership Team

24 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

18 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

14 Nov 2024 08:37:03 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

21 Oct 2024 09:05:25 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

09 Oct 2024 09:18:46 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

14 Aug 2024 16:25:26 By Nasdaq GlobeNewswire

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

07 Aug 2024 08:00:08 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

17 Jun 2024 08:05:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

05 Jun 2024 08:05:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

20 May 2024 08:01:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

15 May 2024 20:00:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

15 May 2024 08:45:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

09 May 2024 08:00:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

18 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

03 Apr 2024 08:05:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

27 Mar 2024 16:15:20 By Nasdaq GlobeNewswire

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

07 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

28 Feb 2024 16:05:00 By Nasdaq GlobeNewswire